Chidamide + Regorafenib in Hepatocellular Carcinoma (HCC)
Status:
Recruiting
Trial end date:
2026-01-31
Target enrollment:
Participant gender:
Summary
This open-label, phase Ib/II, multicenter study evaluated the safety, tolerability, efficacy,
and PK of chidamide in combination with regorafenib in patients with HCC. Chidamide, a
histone deacetylase inhibitor, functions as a tumor inhibitor. Regorafenib, a receptor
tyrosine kinase inhibitor, was approved as second-line systemic treatment for HCC patients.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Great Novel Therapeutics Biotech & Medicals Corporation